Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 1
2012 1
2013 2
2015 3
2016 3
2017 5
2018 7
2019 4
2020 6
2021 1
2022 2
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19.
Clegg LE, Stepanov O, Schmidt H, Tang W, Zhang H, Webber C, Cohen TS, Esser MT, Någård M. Clegg LE, et al. Among authors: webber c. Antimicrob Agents Chemother. 2024 May 2;68(5):e0158723. doi: 10.1128/aac.01587-23. Epub 2024 Mar 27. Antimicrob Agents Chemother. 2024. PMID: 38534112 Free PMC article.
A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age.
Christensen S, Bouguermouh S, Ilangovan K, Pride MW, Webber C, Lockhart SP, Shah R, Kitchin N, Lamberth E, Zhang H, Gao Q, Brock L, Anderson AS, Gruber WC. Christensen S, et al. Among authors: webber c. Vaccine. 2023 Dec 7;41(50):7548-7559. doi: 10.1016/j.vaccine.2023.11.003. Epub 2023 Nov 17. Vaccine. 2023. PMID: 37977942 Free article. Clinical Trial.
A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults Aged 65 to 85 Years.
Remich S, Kitchin N, Peterson J, Li P, Pride MW, Brock L, Anderson AS, Gruber WC, Jansen KU, Lockhart SP, Webber C. Remich S, et al. Among authors: webber c. J Infect Dis. 2024 Feb 14;229(2):367-375. doi: 10.1093/infdis/jiad307. J Infect Dis. 2024. PMID: 37531657 Free PMC article. Clinical Trial.
Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age.
Muñoz FM, Sher LD, Sabharwal C, Gurtman A, Xu X, Kitchin N, Lockhart S, Riesenberg R, Sexter JM, Czajka H, Paulsen GC, Maldonado Y, Walter EB, Talaat KR, Englund JA, Sarwar UN, Hansen C, Iwamoto M, Webber C, Cunliffe L, Ukkonen B, Martínez SN, Pahud BA, Munjal I, Domachowske JB, Swanson KA, Ma H, Koury K, Mather S, Lu C, Zou J, Xie X, Shi PY, Cooper D, Türeci Ö, Şahin U, Jansen KU, Gruber WC; C4591007 Clinical Trial Group. Muñoz FM, et al. Among authors: webber c. N Engl J Med. 2023 Feb 16;388(7):621-634. doi: 10.1056/NEJMoa2211031. N Engl J Med. 2023. PMID: 36791162 Free PMC article. Clinical Trial.
A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5 years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12-14-month-old children.
Cutland CL, Peyrani P, Webber C, Newton R, Cutler M, Perez JL. Cutland CL, et al. Among authors: webber c. Vaccine. 2023 Jan 27;41(5):1153-1160. doi: 10.1016/j.vaccine.2022.11.048. Epub 2023 Jan 6. Vaccine. 2023. PMID: 36621408 Free article. Clinical Trial.
Clostridioides difficile infection (CDI): A pan-European multi-center cost and resource utilization study, results from the Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI).
Wingen-Heimann SM, Davies K, Viprey VF, Davis G, Wilcox MH, Vehreschild MJGT, Lurienne L, Bandinelli PA, Cornely OA, Vilken T, Hopff SM, Vehreschild JJ; COMBACTE-CDI consortium. Wingen-Heimann SM, et al. Clin Microbiol Infect. 2023 May;29(5):651.e1-651.e8. doi: 10.1016/j.cmi.2022.12.019. Epub 2022 Dec 29. Clin Microbiol Infect. 2023. PMID: 36586512
Safety and immunogenicity of different Clostridioides (Clostridium) difficile vaccine formulations in two early phase randomized studies of healthy adults aged 50-85 years.
Lawrence J, Kitchin N, Anderson AS, Pride MW, Jansen KU, Gruber WC, Peng Y, Yi K, Knirsch C, Webber C. Lawrence J, et al. Among authors: webber c. Vaccine. 2021 Sep 24;39(40):5991-6003. doi: 10.1016/j.vaccine.2021.05.028. Epub 2021 Sep 3. Vaccine. 2021. PMID: 34483022 Clinical Trial.
A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years.
Borja-Tabora CFC, Peyrani P, Webber C, Van der Wielen M, Cheuvart B, De Schrevel N, Bianco V, Aris E, Cutler M, Li P, Perez JL. Borja-Tabora CFC, et al. Among authors: webber c. BMC Infect Dis. 2020 Jun 18;20(1):426. doi: 10.1186/s12879-020-05104-5. BMC Infect Dis. 2020. PMID: 32552685 Free PMC article. Clinical Trial.
37 results